The Kidney Foundation of Canada   Report issue

Foundation Phase 2 Phase 3 Phase 4
Founded: Montreal Canada (1964)

Organization Overview

First Clinical Trial
2010
NCT01247311
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

The Kidney Foundation of Canada

Active Ingredients

Drugs in Phase 4 Trials (3)

calcium (1 trial)

denosumab (prolia) (1 trial)

vitamin d3 (2 trials)

Drugs in Phase 3 Trials (1)

curcumin (1 trial)

Drugs in Phase 2 Trials (1)

nicotinamide (1 trial)

Drugs in Other Trials (1)

alteplase (Activase) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Basal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Kidney Diseases (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Skin Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 6